KR20220152276A - 이미다조피리디논 화합물 또는 그 염의 결정 - Google Patents

이미다조피리디논 화합물 또는 그 염의 결정 Download PDF

Info

Publication number
KR20220152276A
KR20220152276A KR1020227034820A KR20227034820A KR20220152276A KR 20220152276 A KR20220152276 A KR 20220152276A KR 1020227034820 A KR1020227034820 A KR 1020227034820A KR 20227034820 A KR20227034820 A KR 20227034820A KR 20220152276 A KR20220152276 A KR 20220152276A
Authority
KR
South Korea
Prior art keywords
peaks
compound
crystals
crystal
diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227034820A
Other languages
English (en)
Korean (ko)
Inventor
히데키 다케우치
요시로 키지마
아키히로 모리야마
Original Assignee
깃세이 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깃세이 야쿠힌 고교 가부시키가이샤 filed Critical 깃세이 야쿠힌 고교 가부시키가이샤
Publication of KR20220152276A publication Critical patent/KR20220152276A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227034820A 2020-03-11 2021-03-10 이미다조피리디논 화합물 또는 그 염의 결정 Withdrawn KR20220152276A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020041453 2020-03-11
JPJP-P-2020-041453 2020-03-11
PCT/JP2021/009405 WO2021182490A1 (ja) 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶

Publications (1)

Publication Number Publication Date
KR20220152276A true KR20220152276A (ko) 2022-11-15

Family

ID=77672382

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034820A Withdrawn KR20220152276A (ko) 2020-03-11 2021-03-10 이미다조피리디논 화합물 또는 그 염의 결정

Country Status (8)

Country Link
US (1) US20230167108A1 (https=)
EP (1) EP4091670A4 (https=)
JP (1) JP7566008B2 (https=)
KR (1) KR20220152276A (https=)
CN (1) CN115279761B (https=)
AU (1) AU2021233433A1 (https=)
CA (1) CA3169000A1 (https=)
WO (1) WO2021182490A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
WO2009029609A1 (en) 2007-08-27 2009-03-05 Wyeth Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US20100137297A1 (en) 2007-05-16 2010-06-03 Fletcher Joan M Spiroindalones
US20110152304A1 (en) 2008-05-08 2011-06-23 Merck Sharp & Dohme Corp. Spiroazaindoles
WO2017066014A1 (en) 2015-10-14 2017-04-20 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
CA2696725A1 (en) * 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
EP3698794A1 (en) * 2009-11-06 2020-08-26 Aerpio Therapeutics, Inc. Compositions and methods for treating colitis
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
JP7458987B2 (ja) * 2018-09-13 2024-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20100137297A1 (en) 2007-05-16 2010-06-03 Fletcher Joan M Spiroindalones
WO2009029609A1 (en) 2007-08-27 2009-03-05 Wyeth Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US20110152304A1 (en) 2008-05-08 2011-06-23 Merck Sharp & Dohme Corp. Spiroazaindoles
WO2017066014A1 (en) 2015-10-14 2017-04-20 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ellen Marks 등, 「Inflamm. Bowel. Dis.」, 2015년, 제21권, 제2호, p.267-275
Guanghui Deng 등, 「Bioorganic & Medicinal Chemistry」, 2013년, 제21권, p.6349-6358
Mun Chiang Chan 등, 「Molecular Aspects of Medicine」, 2016년, 제47-48권, p.54-75
Petr Vachal 등, 「Journal of Medicinal Chemistry」, 2012년, 제55권, p.2945-2959

Also Published As

Publication number Publication date
US20230167108A1 (en) 2023-06-01
JPWO2021182490A1 (https=) 2021-09-16
AU2021233433A1 (en) 2022-10-06
CN115279761A (zh) 2022-11-01
CA3169000A1 (en) 2021-09-16
EP4091670A1 (en) 2022-11-23
JP7566008B2 (ja) 2024-10-11
CN115279761B (zh) 2025-03-14
WO2021182490A1 (ja) 2021-09-16
EP4091670A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7716110B2 (ja) ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用
KR102705376B1 (ko) 화학적 화합물
US20240239735A1 (en) Acid addition salt of rock inhibitor, and crystal form, composition and pharmaceutical use thereof
CN109843873B (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
TWI641602B (zh) 單環吡啶衍生物
CN117800989A (zh) 一类含环外双键、多取代甲基醚结构的化合物及其应用
CN111225896A (zh) 免疫调节剂化合物
WO2024083255A1 (zh) 苄基或噻吩亚甲基取代的氨基喹唑啉衍生物及其作为sos1降解剂的用途
CN113527335A (zh) 作为egfr抑制剂的大环类化合物及其应用
CN109311846B (zh) 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物
WO2023246656A1 (zh) Sos1蛋白降解靶向嵌合体及其组合物、制剂和用途
TW201731841A (zh) 6‐芳基或6‐異芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物
CN112110938B (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
CN106660970B (zh) 喹唑啉衍生物
KR20220152276A (ko) 이미다조피리디논 화합물 또는 그 염의 결정
CN111108083B (zh) 氨基亚甲基环己烷1,3-二酮化合物的用途
CN112979675A (zh) 一种小分子含硫杂环化合物
CN119894908A (zh) Egfr抑制剂和其用途
CN112218858B (zh) 2,6-二氨基-3,4-二氢嘧啶-4-酮衍生物及其在治疗中的用途
HK40083277A (en) Crystal of imidazopyridinone compound or salt thereof
CN116768870A (zh) 具有苄氧基芳基醚结构的化合物及其制备方法和用途
CN115244054B (zh) 次黄嘌呤化合物的晶体
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
WO2025247178A1 (zh) 一类prmt5抑制剂及其组合物和用途
CN121627720A (zh) 大环化合物的制备及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221006

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250609

WITB Written withdrawal of application